Table 2.
Effect of COBI, emtricitabine, and elvitegravir on the cytotoxicity of TFV in human RPTECs
| Compound | CC50 [μM]a for: |
|
|---|---|---|
| Cell viability | LDH release | |
| TFV | >4,000 | >4,000 |
| COBI | 26.2 ± 5.3 | 39.4 ± 0.8 |
| Elvitegravir | 13.7 ± 0.1 | 32.7 ± 0.1 |
| Emtricitabine | >100 | >100 |
| TFV + COBI (2 μM)b | >4,000 | >4,000 |
| TFV + COBI (2 μM) + elvitegravir (4.5 μM) + emtricitabine (8 μM)b | >4,000 | >4,000 |
a
The results represent means ± SD from 4 independent experiments performed in RPTECs from 2 independent donors. CC50 values were determined in parallel from cell viability readout (CellTiter Glo) and from lactate dehydrogenase (LDH) release readout.